🇺🇸 FDA
Pipeline program

Efinopegdutide

6024-013

Phase 2 small_molecule completed

Quick answer

Efinopegdutide for Non-alcoholic Fatty Liver Disease is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Non-alcoholic Fatty Liver Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials